Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $14.25, for a total value of $62,700.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded up $0.15 during mid-day trading on Friday, reaching $14.60. The company’s stock had a trading volume of 247,557 shares, compared to its average volume of 141,344. Atara Biotherapeutics, Inc. has a 52 week low of $11.80 and a 52 week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). equities research analysts forecast that Atara Biotherapeutics, Inc. will post -4 EPS for the current year.

A number of hedge funds have recently bought and sold shares of ATRA. SG Americas Securities LLC bought a new position in Atara Biotherapeutics in the third quarter valued at about $142,000. Voya Investment Management LLC lifted its holdings in Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 1,651 shares during the period. Russell Investments Group Ltd. bought a new position in Atara Biotherapeutics in the third quarter valued at about $170,000. State of Wisconsin Investment Board bought a new position in Atara Biotherapeutics in the second quarter valued at about $252,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 1,369 shares during the period. 85.61% of the stock is currently owned by institutional investors.

ATRA has been the topic of a number of research analyst reports. Jefferies Group reaffirmed a “buy” rating and set a $30.00 price target on shares of Atara Biotherapeutics in a report on Thursday, August 31st. Zacks Investment Research downgraded Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a report on Thursday, November 9th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $20.00 price target on shares of Atara Biotherapeutics in a report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Atara Biotherapeutics presently has an average rating of “Hold” and an average price target of $24.40.

ILLEGAL ACTIVITY NOTICE: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/03/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-4400-shares.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.